HighTower Advisors LLC Makes New $273,000 Investment in Genmab A/S (NASDAQ:GMAB)

HighTower Advisors LLC acquired a new stake in shares of Genmab A/S (NASDAQ:GMAB) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 11,384 shares of the company’s stock, valued at approximately $273,000.

A number of other hedge funds also recently added to or reduced their stakes in GMAB. Verition Fund Management LLC bought a new stake in shares of Genmab A/S in the third quarter worth approximately $709,000. FMR LLC lifted its stake in shares of Genmab A/S by 13.5% during the 3rd quarter. FMR LLC now owns 278,194 shares of the company’s stock valued at $6,782,000 after buying an additional 33,076 shares in the last quarter. Cerity Partners LLC grew its position in shares of Genmab A/S by 14.6% during the third quarter. Cerity Partners LLC now owns 48,003 shares of the company’s stock worth $1,170,000 after purchasing an additional 6,103 shares in the last quarter. Eagle Asset Management Inc. lifted its holdings in shares of Genmab A/S by 10.0% in the third quarter. Eagle Asset Management Inc. now owns 12,356 shares of the company’s stock worth $285,000 after buying an additional 1,121 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Genmab A/S by 94.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 26,104 shares of the company’s stock valued at $636,000 after purchasing an additional 12,654 shares during the last quarter. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

Genmab A/S Stock Up 2.2 %

Shares of NASDAQ GMAB opened at $20.76 on Tuesday. Genmab A/S has a 52-week low of $19.85 and a 52-week high of $32.88. The business’s 50 day moving average is $21.80 and its two-hundred day moving average is $24.75. The firm has a market cap of $13.74 billion, a price-to-earnings ratio of 20.16, a PEG ratio of 0.67 and a beta of 0.96.

Genmab A/S (NASDAQ:GMAB) last released its earnings results on Wednesday, November 6th. The company reported $0.29 earnings per share for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.03). The firm had revenue of $816.10 million for the quarter, compared to analysts’ expectations of $838.20 million. Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. During the same quarter in the previous year, the company posted $0.47 earnings per share. Analysts anticipate that Genmab A/S will post 1.28 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have commented on GMAB shares. HC Wainwright reissued a “buy” rating and issued a $50.00 price objective on shares of Genmab A/S in a research note on Wednesday, October 16th. BMO Capital Markets restated an “outperform” rating and set a $48.00 price objective (up from $46.00) on shares of Genmab A/S in a report on Friday, November 8th. Redburn Atlantic assumed coverage on Genmab A/S in a research report on Tuesday, October 8th. They set a “buy” rating for the company. Morgan Stanley reiterated an “equal weight” rating and set a $31.00 target price on shares of Genmab A/S in a report on Wednesday, September 11th. Finally, Truist Financial reduced their price objective on shares of Genmab A/S from $53.00 to $50.00 and set a “buy” rating for the company in a research note on Monday, September 9th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, Genmab A/S has an average rating of “Moderate Buy” and an average target price of $45.20.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.